H eart failure (HF) is a global health challenge due to ageing populations and increasing burden of disease (1) . Older HF patients have higher rates of preserved ejection fraction (HFpEF) and higher numbers of females and comorbidities (2) . There are uncertainties in diagnosis of HF in the elderly, who may present with atypical symptoms, and the evidence base for conventional treatments is weaker especially for HFpEF (3) .
The exact pathophysiologic mechanisms responsible for HFpEF are not clear. The condition is thought to be mediated by diastolic dysfunction (including myocardial hypertrophy, increased ventricular stiffness, and prolonged ventricular relaxation), but a simple and universal definition of HFpEF is lacking (4) . Unfortunately, the therapeutic paradigm that has been successful in heart failure with reduced ejection fraction (HFrEF) has yet to be convincingly demonstrated in HFpEF. Without effective therapies, hospitalizations for HFpEF have increased, and risk of death and hospitalization appear similar to those of HFrEF (5) . As a result, a dichotomy in outcomes has emerged between these 2 seemingly related pathophysiological states.
The physiological mechanisms of beta blockers appear to be well understood in HFrEF, blocking sympathetic neural activity, preventing catecholamine elevation, reducing heart rate, and reducing proapoptotic and cardiotoxic effects of cyclic adenosine monophosphate-mediated calcium overload (6) .
Several large trials and an individual patient data meta-analysis confirm an overall absolute reduction in the risk of death with beta blockers compared to placebo (7). However there was little evidence of benefit in patients with atrial fibrillation (hazard ratio: 0.97 compared to 0.73 for sinus rhythm).
The apparent benefit of the composite of all-cause mortality and cardiovascular hospitalization in the SENIORS trial in patients with EF >35% (mean EF: 49%) was found to be similar to that in patients with EF #35% (mean: 28%), but mortality benefits appeared to be attenuated with higher EF (8) . Other subgroups in whom there are doubts about efficacy of beta blockers are the elderly, women, and those with diabetes, and further analyses from the Beta Blockers Heart Failure Collaborative Group will help to clarify effects in these important subgroups. Trials; is on an advisory board for AstraZeneca; has received research grants from Menarini International; and has received honoraria from AstraZeneca, Novartis, and Pfizer. Dr. Gollop has reported that he has no relationships relevant to the contents of this paper to disclose. 
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